129 related articles for article (PubMed ID: 21131659)
1. MADOR: a new tool to calculate decrease of effective doses in human after DTPA therapy.
Fritsch P; Grémy O; Hurtgen C; Bérard P; Grappin L; Poncy JL
Radiat Prot Dosimetry; 2011 Mar; 144(1-4):371-5. PubMed ID: 21131659
[TBL] [Abstract][Full Text] [Related]
2. Modelling of bioassay data from a Pu wound treated by repeated DTPA perfusions: biokinetics and dosimetric approaches.
Fritsch P; Grappin L; Guillermin AM; Fottorino R; Ruffin M; Mièle A
Radiat Prot Dosimetry; 2007; 127(1-4):120-4. PubMed ID: 17562647
[TBL] [Abstract][Full Text] [Related]
3. Biokinetic modelling of DTPA decorporation therapy: the CONRAD approach.
Breustedt B; Blanchardon E; Berard P; Fritsch P; Giussani A; Lopez MA; Luciani A; Nosske D; Piechowski J; Schimmelpfeng J; Sérandour AL
Radiat Prot Dosimetry; 2009 Feb; 134(1):38-48. PubMed ID: 19351653
[TBL] [Abstract][Full Text] [Related]
4. Simplified structure of a new model to describe urinary excretion of plutonium after systemic, liver or pulmonary contamination of rats associated with Ca-DTPA treatments.
Fritsch P; Sérandour AL; Grémy O; Phan G; Tsapis N; Abram MC; Renault D; Fattal E; Benech H; Deverre JR; Poncy JL
Radiat Res; 2009 Jun; 171(6):674-86. PubMed ID: 19580474
[TBL] [Abstract][Full Text] [Related]
5. Treatment of human contamination with plutonium and americium: would orally administered Ca- or Zn-DTPA be effective?
Taylor DM; Hodgson SA; Stradling N
Radiat Prot Dosimetry; 2007; 127(1-4):469-71. PubMed ID: 17556346
[TBL] [Abstract][Full Text] [Related]
6. The CONRAD approach to biokinetic modeling of DTPA decorporation therapy.
Breustedt B; Blanchardon E; Bérard P; Fritsch P; Giussani A; Lopez MA; Luciani A; Nosske D; Piechowski J; Schimmelpfeng J; Sérandour AL
Health Phys; 2010 Oct; 99(4):547-52. PubMed ID: 20838097
[TBL] [Abstract][Full Text] [Related]
7. Ustur whole body case 0269: demonstrating effectiveness of i.v. CA-DTPA for Pu.
James AC; Sasser LB; Stuit DB; Glover SE; Carbaugh EH
Radiat Prot Dosimetry; 2007; 127(1-4):449-55. PubMed ID: 18227077
[TBL] [Abstract][Full Text] [Related]
8. Lauriston S. Taylor Lecture: the quest for therapeutic actinide chelators.
Durbin PW
Health Phys; 2008 Nov; 95(5):465-92. PubMed ID: 18849679
[TBL] [Abstract][Full Text] [Related]
9. Treatment of actinide exposures: a review of Ca-DTPA injections inside CEA-COGEMA plants.
Grappin L; Berard P; Menetrier F; Carbone L; Courtay C; Castagnet X; Le Goff JP; Neron MO; Piechowski J
Radiat Prot Dosimetry; 2007; 127(1-4):435-9. PubMed ID: 17940101
[TBL] [Abstract][Full Text] [Related]
10. Three plutonium chelation cases at Los Alamos National Laboratory.
Bertelli L; Waters TL; Miller G; Gadd MS; Eaton MC; Guilmette RA
Health Phys; 2010 Oct; 99(4):532-8. PubMed ID: 20838095
[TBL] [Abstract][Full Text] [Related]
11. Actinide handling after wound entry with local or systemic decorporation therapy in the rat.
Griffiths NM; Coudert S; Renault D; Wilk JC; Van der Meeren A
Int J Radiat Biol; 2014 Nov; 90(11):989-95. PubMed ID: 24456546
[TBL] [Abstract][Full Text] [Related]
12. Structure of a single model to describe plutonium and americium decorporation by DTPA treatments.
Fritsch P; Sérandour AL; Grémy O; Phan G; Tsapis N; Fattal E; Benech H; Deverre JR; Poncy JL
Health Phys; 2010 Oct; 99(4):553-9. PubMed ID: 20838098
[TBL] [Abstract][Full Text] [Related]
13. Design and functionalities of the MADOR® software suite for dose-reduction management after DTPA therapy.
Leprince B; Fritsch P; Bérard P; Roméo PH
Radiat Prot Dosimetry; 2016 Mar; 168(3):350-7. PubMed ID: 25999333
[TBL] [Abstract][Full Text] [Related]
14. Decorporation of plutonium by pulmonary administration of Ca-DTPA dry powder: a study in rat after lung contamination with different plutonium forms.
Sérandour AL; Tsapis N; Gervelas C; Grillon G; Fréchou M; Deverre JR; Bénech H; Fattal E; Fritsch P; Poncy JL
Radiat Prot Dosimetry; 2007; 127(1-4):472-6. PubMed ID: 17562654
[TBL] [Abstract][Full Text] [Related]
15. MEDOR, a didactic tool to support interpretation of bioassay data after internal contamination by actinides.
Mièle A; Blanchin N; Raynaud P; Quesne B; Giraud JM; Fottorino R; Bérard P; Ansoborlo E; Franck D; Blanchardon E; Challeton-de Vathaire C; Lebaron-Jacobs L; Poncy JL; Piechowski J; Fritsch P
Radiat Prot Dosimetry; 2007; 127(1-4):350-5. PubMed ID: 17562646
[TBL] [Abstract][Full Text] [Related]
16. A case of wound intake of plutonium isotopes and 241Am in a human: application and improvement of the NCRP wound model.
Schadilov AE; Belosokhov MV; Levina ES
Health Phys; 2010 Oct; 99(4):560-7. PubMed ID: 20838099
[TBL] [Abstract][Full Text] [Related]
17. Development of a New Chelation Model: Bioassay Data Interpretation and Dose Assessment after Plutonium Intake via Wound and Treatment with DTPA.
Dumit S; Miller G; Klumpp JA; Poudel D; Bertelli L; Waters TL
Health Phys; 2020 Dec; 119(6):715-732. PubMed ID: 33196524
[TBL] [Abstract][Full Text] [Related]
18. Diethylene-triamine-penta-acetate administration protocol for radiological emergency medicine in nuclear fuel reprocessing plants.
Jin Y
Hemoglobin; 2008; 32(1-2):199-206. PubMed ID: 18274997
[TBL] [Abstract][Full Text] [Related]
19. Skin absorption of actinides: influence of solvents or chelates on skin penetration ex vivo.
Tazrart A; Bolzinger MA; Coudert S; Lamart S; Miller BW; Angulo JF; Briançon S; Griffiths NM
Int J Radiat Biol; 2017 Jun; 93(6):607-616. PubMed ID: 28276896
[TBL] [Abstract][Full Text] [Related]
20. Toward an optimal DTPA therapy for decorporation of actinides: time-dose relationships for plutonium in the dog. I.
Guilmette RA; Moretti ES; Lindenbaum A
Radiat Res; 1979 Jun; 78(3):415-28. PubMed ID: 221958
[No Abstract] [Full Text] [Related]
[Next] [New Search]
